- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03094819
PROTECT2: Diabetes Care - Eye Exam
The PROTECT2 pilot study is a single cohort prospective study to gather pilot data and finalize operational details of the main study.
The PROTECT2 main study is a prospective randomized controlled multi-center three group clinical trial. The primary endpoint is the percentage of participants in each study group obtaining a qualified eye examination within 12 months of their enrollment in the study.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
The primary objective of this study is to compare the qualified eye examination rate in two groups of patients with diabetes receiving a new intervention, with the rate in a control group of patients with diabetes receiving usual care only.
Secondary objectives are to:
- Improve our understanding of the barriers to obtaining eye examinations;
- Evaluate the communication between eye care providers (ECP) and referring primary care providers (PCP), as determined by rates of follow-up reports sent and received;
- Characterize eye examinations provided to patients with diabetes;
- Explore the relationships between systemic variables known to affect the severity of diabetic retinopathy and the patient's risk of vision-threatening diabetic retinopathy.
Design and Primary Endpoint
- The pilot study is a single cohort prospective study to gather pilot data and finalize operational details of the main study.
- The main study is a prospective randomized controlled multi-center three group clinical trial. The primary endpoint is the percentage of participants in each study group obtaining a qualified eye examination within 12 months of their enrollment in the study.
Interventions and Duration
Eligible patients will be randomized to one of three groups in a 1:1:2 ratio.
- Group 1. Participants randomized to Group 1 will be the control group. They will be observed while they receive usual eye care without any study intervention.
- Financial Incentive. Participants randomized to the Financial Incentive group will be offered a financial incentive in conjunction with their usual eye care. They will receive usual care and a $25 payment if they obtain a confirmed eye examination.
- Retinal Care DR Service. Participants randomized to the Retinal Care DR Service group will receive: (1) point of care risk assessment for vision- threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision- threatening diabetic retinopathy.
All participants, regardless of their group, will be in the study for about one year.
Sample Size and Population Patients meeting the inclusion and exclusion criteria will be recruited at up to four (4) study sites until the sample size of 4,500 participants is enrolled. This includes up to 500 patients at each site in the pilot study, and weighted randomization in the main study to ensure enrollment of approximately 500 patients in the Retinal Care DR Service group at each site to evaluate the operational characteristics of the Retinal Care DR Service in populations representative of those anticipated in commercial use.
Studietype
Inschrijving (Verwacht)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104-5065
- Dean McGee Eye Institute
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Diagnosed diabetes using the criteria documented in the 2016 Physician Quality Reporting System (PQRS) Measure Specifications Manual for Claims and Registry Reporting of Individual Measures.
- 18 through 75 years of age
- Have a PCP appointment scheduled within 90 days of the date of medical record review.
Exclusion Criteria:
- Patients not diagnosed with diabetes
- History of photosensitive epilepsy
- Inability or unwillingness of the participant to give verbal or written informed consent.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Onderzoek naar gezondheidsdiensten
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Geen tussenkomst: Group 1
Participants randomized to Group 1 will be the control group.
They will be observed while they receive usual eye care without any study intervention.
|
|
Experimenteel: Financial Incentive
Participants randomized to the Financial Incentive group will be offered a financial incentive in conjunction with their usual eye care.
They will receive usual care and a $25 payment if they obtain a confirmed eye examination.
|
Participants will receive usual care and a $25 payment if they obtain a confirmed eye examination.
|
Experimenteel: Retinal Care DR
Participants randomized to the Retinal Care DR Service group will receive: (1) point of care risk assessment for vision-threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision-threatening diabetic retinopathy.
|
Participants will receive: (1) point of care risk assessment for vision- threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision- threatening diabetic retinopathy.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Qualified eye examination rate
Tijdsspanne: 12 months
|
Percent of participants in each study group obtaining a qualified eye examination.
|
12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
PCP report rate
Tijdsspanne: 12 months
|
Percent of eye examinations with a follow-up report sent to the PCP.
|
12 months
|
PCP medical record rate
Tijdsspanne: 12 months
|
Percent of eye examinations with a follow-up report sent to the PCP, where the results of the follow-up report are documented in the PCP medical record.
|
12 months
|
Eye examination barriers
Tijdsspanne: 12 months
|
Descriptive analysis of barriers to obtaining an eye examination.
|
12 months
|
Increased risk group eye examination rate
Tijdsspanne: 12 months
|
Percent of participants at increased risk for vision-threatening diabetic retinopathy who are subsequently seen by an eye care provider.
|
12 months
|
Eye examination findings
Tijdsspanne: 12 months
|
Descriptive analysis of eye examination findings for participants at increased risk for vision-threatening diabetic retinopathy.
|
12 months
|
Eye examination components
Tijdsspanne: 12 months
|
Descriptive analysis of eye examination components for participants at increased risk for vision-threatening diabetic retinopathy.
|
12 months
|
Eye care costs
Tijdsspanne: 12 months
|
Numerical analysis of eye care costs using provider reported and claims data.
|
12 months
|
Risk correlations
Tijdsspanne: 12 months
|
Correlation analysis of systemic variables known to affect the severity of diabetic retinopathy and retinal specialist interpretation of participant's risk assessment data.
|
12 months
|
Participant perceptions
Tijdsspanne: 12 months
|
Descriptive analysis of participant perceptions of the Retinal Care DR Service.
|
12 months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Ronald M Kingsley, MD, Dean McGee Eye Institute / University of Oklahoma Health Sciences Center
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 09-PLN-001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .